Cardiovascular disease Archives

News and Trends 11 Dec 2015

Biotech of the Week: Zealand Pharma, Biotech Success Story made in Denmark

This week we say farewell to Zurich and head North, through Germany where we arrive at our next destination, the capital city of Denmark, Copenhagen. This amazing city is famous for the Little Mermaid Statue, the autonomous neighborhood of Christiania and Tivoli Gardens Amusement Park. It is also home to our biotech of the week: Zealand […]

December 11, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 27 Nov 2015

18,000 Patients Enrolled for One of the Most Comprehensive Trials Against Cholesterol

Sanofi & Regeneron have completed enrollment in the global Phase III for Praulent (alirocumab), which is evaluating its potential cardiovascular benefits for patients with acute coronary syndrome (ACS). The ‘Odyssey Outcomes’ Study has enrolled around 18,000 patients for its trial (phwoar), and if it shows positive results could be a huge success for Sanofi and […]

November 27, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 16 Nov 2015

Interview with the CEO of Genfit – The Billion Euro Liver Biotech on its phase III NASH Drug

Interview with Jean-François Mouney (Chairman and CEO of Genfit) at the ‘Liver Meeting 2015‘ congress for the American Association for the study of Liver disease (AASLD) on Friday in San Francisco (US). Genfit is the European leader in NASH research (Non-alcoholic steatohepatitis), today making the news again at AASLD in San Francisco. The company, which […]

November 16, 2015 - 5 minutesmins - By Dani Bancroft

News and Trends 30 Sep 2015

Gecko’s Heart surgery glue the new Cover of Science’s Translational Medicine

Gecko Biomedical is a young Parisian biotech which is now featured on the front cover of the Science Journal for Translational Medicine. We explore their surgery adhesive tech inspired by natural stickiness of molluscan slugs, and their latest proof of its application in heart surgery. Gecko Biomedical was only founded in 2013 by a rockstar […]

September 30, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 24 Sep 2015

Heart Attacks: TiGenix advances its cardiac stem-cell therapy

Belgian TiGenix NV released the phase I results of their cardiac stem-cell therapy at the Congress of the European Society of Cardiology (ESC) in London earlier this month. In July, TiGenix acquired the smaller biotech CoreTherapix with the AlloCSC-01 pipeline. This stem-cell therapy is for regeneration of heart muscle following a heart attack, and is currently […]

September 24, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 17 Sep 2015

Forbion’s Dutch biotech draws Cali’s Amgen into €1.36Bn deal

Californian Amgen has announced its plans to acquire the Dutch pharma Dezima off of Forbion for €265M upfront. An additional €1.1Bn will be paid through development on their cardiovascular drug candidate which has shown good results in its phase II trial. Amgen is set to buy out Forbion’s portfolio of Amsterdam based Dezima Pharma, a […]

September 17, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 1 Sep 2015

Researcher in Cardiovascular disease? Apply to this new €1,6M Competition for the next treatment

A new research competition is born. The European Society of Cardiology and Boehringer Ingelheim will award €400k to four research projects treating cardiovascular diseases. Big Pharmas like to give a push to aspiring research projects within their field. GSK is a key partner of the world’s largest life science startup accelerator, namely OneStart. Sanofi is engaged […]

September 1, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 12 Aug 2015

A Tale of Love for UniQure and Bristol-Myers Squibb

In May, Bristol-Myers Squibb (BMS) nailed down the exclusive access to uniQure’s gene therapy platform to treat cardiovascular diseases. Everything seems to work out fine as BMS paid $53M (€47M) for three new targets and additional shares to own nearly 10% of the company. UniQure is a Dutch pioneer in the field of gene therapy. It […]

August 12, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 5 Aug 2015

AstraZeneca Adds New Antisense Drugs to its Pipeline

Isis Pharmaceuticals and AstraZeneca extend their collaboration to discover and develop antisense therapies. After cancer, the partners are now targeting cardiovascular, metabolic and renal diseases. Antisense drugs are short, chemically modified, single-stranded nucleic acids (antisense oligonucleotides) that have the ability to target any gene product of interest. They offer new opportunities for therapeutic intervention because […]

August 5, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 27 Jul 2015

Hunt for Hypercholesterolemia Drug Approval: Sanofi vs Amgen vs Pfizer

Cardiovascular diseases kill around 2.6 million people each year and embody one of the biggest healthcare markets in the World. Not surprising to see Big Pharmas/Biotechs overactive in this field. What are their plans? Today, Sanofi‘s hypercholesterolemia therapy Praluent was recommended to the European market. It is a fully human monoclonal antibody developed in collaboration with the American Big Biotech Regeneron. But Amgen announced […]

July 27, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 3 Jul 2015

Nobel Prize’s company start gathering robust clinical data in two phases II

Cell Therapy’s Tendoncel, a topical gel for the treatment of severe tendon injuries, has successfully completed its phase II. The optimistic results from the clinical trial add to those of the company’s leading product, released last week. The UK company has finally started to collect strong clinical data to support its approach. Cell Therapy Limited […]

July 3, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 19 Jun 2015

Celyad, the new face of Cardio3, is launching an IPO on NASDAQ

[UPDATE 19/06/2015]: Yesterday, Celyad launched its IPO on NASDAQ and the closing is expected to occur on 24 June 2015. Celyad, formely known as Cardio3, is preparing to cross the Atlantic to launch an IPO on NASDAQ. The company, which is already listed on Euronext Paris and Euronext Brussels, aims to raise €103.2M ($115 million) on […]

June 19, 2015 - 2 minutesmins - By Lourdes Riquelme

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Cardiovascular disease

Biotech of the Week: Zealand Pharma, Biotech Success Story made in Denmark

18,000 Patients Enrolled for One of the Most Comprehensive Trials Against Cholesterol

Interview with the CEO of Genfit – The Billion Euro Liver Biotech on its phase III NASH Drug

Gecko’s Heart surgery glue the new Cover of Science’s Translational Medicine

Heart Attacks: TiGenix advances its cardiac stem-cell therapy

Forbion’s Dutch biotech draws Cali’s Amgen into €1.36Bn deal

Researcher in Cardiovascular disease? Apply to this new €1,6M Competition for the next treatment

A Tale of Love for UniQure and Bristol-Myers Squibb

AstraZeneca Adds New Antisense Drugs to its Pipeline

Hunt for Hypercholesterolemia Drug Approval: Sanofi vs Amgen vs Pfizer

Nobel Prize’s company start gathering robust clinical data in two phases II

Celyad, the new face of Cardio3, is launching an IPO on NASDAQ

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!